Summary
• Clearside Biomedical, Inc. (CLSD) shares fell 24.2% to $0.6824 amid efforts to pursue a strategic sale during Chapter 11 proceedings.
• The company filed for Chapter 11 to maximize stakeholder value and highlighted its SCS Microinjector® platform and CLS-AX TKI program potential.
• Analysts maintain a “Buy” rating despite a surprise loss of $1.14 per share and ongoing market volatility.
Clearside Biomedical, Inc. (NASDAQ: CLSD) saw a sharp decline of 24.2%, trading at $0.6824 in intraday trading, a significant drop from its previous close. This move comes amid routine trading, following the company’s recent announcement to pursue a strategic sale through a voluntary Chapter 11 process.
Chapter 11 Filing Signals Strategic Shift
On November 24, 2025, Clearside Biomedical announced that it has filed for voluntary Chapter 11 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware. This action is intended to maximize stakeholder value through a structured process. The company highlighted the potential of its validated SCS Microinjector® delivery platform, which is anchored by a commercial product and several licensing collaborations that may provide future royalty revenue.
The filing was also accompanied by information about the company’s CLS-AX TKI program, which includes a Phase 3-ready asset for treating wet age-related macular degeneration (AMD) and pathways for Phase 2B/3 trials in diabetic retinopathy. Additionally, the company has IND-ready programs focusing on geographic atrophy and diabetic macula edema.
Market Performance and Technical Indicators
Clearside’s shares have been volatile, with a current RSI of 18.15 indicating oversold conditions. The stock’s average volume over the past 10 days is approximately 887,347 shares, compared to a 3-month average of about 150,616 shares, suggesting a recent uptick in trading activity. The 52-week range shows a significant downtrend, with a high of $12.45 and a low of $0.82, reflecting a yearly performance drop of approximately 76%.
Recent Analyst Sentiment
Despite the turbulent market conditions, Clearside holds a “Buy” rating from analysts, signifying some optimism among market watchers regarding its long-term potential. The latest earnings report showcased a surprise loss of $1.14 per share against an estimate of $0.67, with analysts reacting to the company’s cited challenges and strategic maneuvers.
With the current situation, investors are closely monitoring Clearside’s actions as it navigates through the Chapter 11 process, evaluating the potential recovery mechanisms and their implications for future growth.